The FDA has approved relacorilant (Lifyorli, Corcept Therapeutics) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal ...
The FDA approved relacorilant (Lifyorli) in combination with nab-paclitaxel (Abraxane) for the treatment of adults with ...
March 25 (Reuters) - Corcept Therapeutics shares jumped more than 32% to nearly a two-month high on Wednesday after the U.S.
Researchers have uncovered an early survival response in ovarian cancer cells that may limit the effectiveness of widely used ...
Preview this article 1 min In ovarian cancer alone — the fifth-most common cause of death in women — Lifyorli could ring up ...
FDA authorization covers platinum-resistant disease after 1–3 prior lines, with mandatory prior bevacizumab exposure, ...
FDA approval of Lifyorli plus nab-paclitaxel offers a new option for platinum-resistant epithelial ovarian cancer after 1 to 3 prior systemic regimens.
The approval is based on the results of Corcept’s Phase 3 ROSELLA trial, which showed improvements in both progression-free survival and overall survival. ・The approval covers adults with ...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...
Ovarian cancer is not a silent tumour, it just masquerades in the form of digestive distress and gets worse over time. If you ...
Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer
The FDA has given the all-clear to Corcept’s class-first Lifyorli (relacorilant) to treat adults with platinum-resistant ...
In the last month, I had a revelation about my illness. Today is my birthday! I was not so sure I would make it today as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results